Stem Cell Therapy for Cerebral Palsy – Video
October 13th, 2011 1:09 pmhttp://www.cellmedicine.com the scientific basis for using cord blood stem cells to treat cerebral palsy
Read the original post:
Stem Cell Therapy for Cerebral Palsy - Video
Chocolate compounds fight high cholesterol
October 9th, 2011 4:07 pmChocolate has received a lot of attention for being a treasure trove of nutritional goodness. Polyphenols in cacao beans are linked to promoting heart, brain, and liver health, which has sparked renewed interest in chocolate as a medicinal food. And a new study adds to the growing list of benefits, showing that chocolate polyphenols also help to lower bad cholesterol.
Published in the journal Diabetic Medicine, the study tested the effects of polyphenol-rich chocolate in a group of 12 volunteers with type-2 diabetes. After 16 weeks, the researchers from Hull University in the U.K. discovered that the polyphenols helped lower participants' bad cholesterol levels while raising good cholesterol levels.
"Chocolate with a high cocoa content should be included in the diet of individuals with type-2 diabetes as part of a sensible, balanced approach to diet and lifestyle," said professor Steve Akin, author of the study. Read more...
Immunice for Immune Support
International Stem Cell Corp. Chairman Kenneth Aldrich Comments on Recent TIME Article “A Stem Cell First: Using the ‘Dolly’ Method on Human Cells”
October 9th, 2011 4:07 pm“Since we at International Stem Cell Corporation (trading symbol: ISCO.OB) are licensees of some of the key intellectual property necessary to use SCNT in therapeutic products, we were delighted to read about this new discovery. However, what disappointed us somewhat was the failure of most news reports to mention that a technology already exists that solves the same ethical problems and has the potential also to solve many of the problems of immune rejection that worry scientists who are working with cells obtained from fertilized embryos.
That technology is called "Parthenogenesis" and results in a "cell line" that can provide an essentially unlimited supply of human cells for a wide range of therapeutic purposes, yet does not involve the destruction of any fertilized embryo and results in cells that can be matched to large groups of people who may not even know the patient, much like the way blood from donors can be stored and used by accident victims as needed. Unlike the SCNT cells, parthenogenetic cells require no genetic manipulation or insertion of foreign DNA.
Our scientists at ISCO created and patented the process for making such human parthenogenetic stem cell lines and have already successfully made liver cells, cornea cells, retina cells and nerve cells from those cell lines. Each of these applications is being studied as a possible future source of transplanted cells to treat diseases such as Parkinson's, Liver Disease, Macular Degeneration, and others.
To learn more about parthenogenesis, visit our website at http://www.internationalstemcell.com or click on ISCO.OB at any financial web site for information about our company.”
Kenneth C. Aldrich
Chairman
International Stem Cell Corporation
TIME Article – A Stem Cell First: Using the 'Dolly' Method on Human Cells
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Names Dr. Andrey Semechkin as Co-Chairman and Kurt May as President and Chief Operating Officer
October 9th, 2011 4:07 pmInternational Stem Cell Corporation (OTCBB:ISCO) today announced that its Board of Directors designated Dr. Andrey Semechkin, the Company's Chief Executive Officer, as a Co-Chairman with the Company's founder, Kenneth Aldrich, and also named Kurt May as President and Chief Operating Officer, effective immediately. Mr. May is currently Senior Vice President and this represents both a promotion and the delegation of additional duties and responsibilities consistent with his increasingly important role in the future of ISCO.
Dr. Semechkin commented, "Kurt May is an extremely capable executive who has managed both a multi-billion dollar public company and a successful life sciences startup company. His willingness to assume operational responsibilities for ISCO will allow me, as CEO, to focus more intently on scientific and strategic initiatives that are central to developing ISCO into a major force in the world of stem cell therapy. Working together with the fine team of executives and scientists already within ISCO, I have high hopes and confidence we can reach that goal."
Prior to joining ISCO, Mr. May was a senior executive with GTE Corporation and with PriceSmart, Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and Assistant Dean of UCSD's Rady School of Management from 2005 to 2009.
During his tenure as PriceSmart's Chief Operating Officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability, and expanding staff from 356 to more than 4,200.
"In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success," said Kenneth Aldrich, Co-Founder and Co-Chairman of ISCO.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Chocolate compounds fight high cholesterol
October 9th, 2011 4:05 pmChocolate has received a lot of attention for being a treasure trove of nutritional goodness. Polyphenols in cacao beans are linked to promoting heart, brain, and liver health, which has sparked renewed interest in chocolate as a medicinal food. And a new study adds to the growing list of benefits, showing that chocolate polyphenols also help to lower bad cholesterol.
Published in the journal Diabetic Medicine, the study tested the effects of polyphenol-rich chocolate in a group of 12 volunteers with type-2 diabetes. After 16 weeks, the researchers from Hull University in the U.K. discovered that the polyphenols helped lower participants' bad cholesterol levels while raising good cholesterol levels.
"Chocolate with a high cocoa content should be included in the diet of individuals with type-2 diabetes as part of a sensible, balanced approach to diet and lifestyle," said professor Steve Akin, author of the study. Read more...
Immunice for Immune Support
International Stem Cell Corp. Chairman Kenneth Aldrich Comments on Recent TIME Article “A Stem Cell First: Using the ‘Dolly’ Method on Human Cells”
October 9th, 2011 4:05 pm“Since we at International Stem Cell Corporation (trading symbol: ISCO.OB) are licensees of some of the key intellectual property necessary to use SCNT in therapeutic products, we were delighted to read about this new discovery. However, what disappointed us somewhat was the failure of most news reports to mention that a technology already exists that solves the same ethical problems and has the potential also to solve many of the problems of immune rejection that worry scientists who are working with cells obtained from fertilized embryos.
That technology is called "Parthenogenesis" and results in a "cell line" that can provide an essentially unlimited supply of human cells for a wide range of therapeutic purposes, yet does not involve the destruction of any fertilized embryo and results in cells that can be matched to large groups of people who may not even know the patient, much like the way blood from donors can be stored and used by accident victims as needed. Unlike the SCNT cells, parthenogenetic cells require no genetic manipulation or insertion of foreign DNA.
Our scientists at ISCO created and patented the process for making such human parthenogenetic stem cell lines and have already successfully made liver cells, cornea cells, retina cells and nerve cells from those cell lines. Each of these applications is being studied as a possible future source of transplanted cells to treat diseases such as Parkinson's, Liver Disease, Macular Degeneration, and others.
To learn more about parthenogenesis, visit our website at http://www.internationalstemcell.com or click on ISCO.OB at any financial web site for information about our company.”
Kenneth C. Aldrich
Chairman
International Stem Cell Corporation
TIME Article – A Stem Cell First: Using the 'Dolly' Method on Human Cells
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Names Dr. Andrey Semechkin as Co-Chairman and Kurt May as President and Chief Operating Officer
October 9th, 2011 4:05 pmInternational Stem Cell Corporation (OTCBB:ISCO) today announced that its Board of Directors designated Dr. Andrey Semechkin, the Company's Chief Executive Officer, as a Co-Chairman with the Company's founder, Kenneth Aldrich, and also named Kurt May as President and Chief Operating Officer, effective immediately. Mr. May is currently Senior Vice President and this represents both a promotion and the delegation of additional duties and responsibilities consistent with his increasingly important role in the future of ISCO.
Dr. Semechkin commented, "Kurt May is an extremely capable executive who has managed both a multi-billion dollar public company and a successful life sciences startup company. His willingness to assume operational responsibilities for ISCO will allow me, as CEO, to focus more intently on scientific and strategic initiatives that are central to developing ISCO into a major force in the world of stem cell therapy. Working together with the fine team of executives and scientists already within ISCO, I have high hopes and confidence we can reach that goal."
Prior to joining ISCO, Mr. May was a senior executive with GTE Corporation and with PriceSmart, Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and Assistant Dean of UCSD's Rady School of Management from 2005 to 2009.
During his tenure as PriceSmart's Chief Operating Officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability, and expanding staff from 356 to more than 4,200.
"In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success," said Kenneth Aldrich, Co-Founder and Co-Chairman of ISCO.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
The New World of Medicine: Stem Cell Therapy
October 6th, 2011 6:17 pmIn this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?
Read the original:
The New World of Medicine: Stem Cell Therapy
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
October 6th, 2011 6:17 pmmetromd.net Stem Cell Therapy for Repairing Joint Injuries | Stem Cell Therapy is effective in many orthopedic applications. Restore function and relieve pain from torn ligaments, tendons and damaged cartilage.
Go here to see the original:
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
The Spinal Cord Journey – Stem cell therapy stories from three spinal cord injury patients
October 6th, 2011 6:17 pmA short film about three spinal cord injury patients who share their stories of tragedy, hope and recovery following stem cell treatments for spinal cord injury at the Stem Cell Institute in Panama City, Panama. See them demonstrate their improvements by lifting themselves up, standing and even walking.
Continue reading here:
The Spinal Cord Journey - Stem cell therapy stories from three spinal cord injury patients
A Touch of Love® – InGeneron – Stem Cell Therapy Interview
October 6th, 2011 2:49 pmPawzzzz for the NEWS! - Produced by A Touch of Love® Inc. http://WWW.ATOUCHOFLOVE.CA - The wonderful new world with Stem Cell Therapy now being accepted in Canada. Curious on how stem cell therapy works
See more here:
A Touch of Love® - InGeneron - Stem Cell Therapy Interview
Stem Cell Therapy for Cerebral Palsy – Holly Catalano
October 5th, 2011 9:57 pmHolly is now able to crawl and sit up on her own just 7 weeks after her second treatment for cerebral palsy at the Stem Cell Institute in Panama City, Panama.
Read the original here:
Stem Cell Therapy for Cerebral Palsy - Holly Catalano
The Spinal Cord Journey – Stem cell therapy stories from three spinal cord injury patients
October 5th, 2011 9:57 pmA short film about three spinal cord injury patients who share their stories of tragedy, hope and recovery following stem cell treatments for spinal cord injury at the Stem Cell Institute in Panama City, Panama.
More here:
The Spinal Cord Journey - Stem cell therapy stories from three spinal cord injury patients
Human Embryonic Stem Cell Therapy: Pathway to the Clinic
October 5th, 2011 9:57 pmThomas Okarma, MD, PhD -- Geron Corporation, USA; From the SBS Symposium Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine. Held in Boston, MA, USA - September 2-3, 2009.
Original post:
Human Embryonic Stem Cell Therapy: Pathway to the Clinic
Regenerative Medicine and Applications of Stem Cell Research
October 5th, 2011 11:29 am(June 1, 2010) Renee Reijo Pera, Ph.D., and Professor Michael Longaker discuss the future of regenerative medicine and the promise that stem cell research holds for this field. During the final quarter of the Stanford Mini Med School, some of the most timely and important topics in contemporary medicine and the biosciences are addressed.
Visit link:
Regenerative Medicine and Applications of Stem Cell Research
Adult Stem Cell Therapy for Multiple Sclerosis
October 5th, 2011 11:29 amsee http://www.cellmedicine.com or http://www.stemnow.com
Read the original here:
Adult Stem Cell Therapy for Multiple Sclerosis
" Embryonic" and "Adult" Stem Cell Research explained by David Kupelian
October 5th, 2011 9:27 amOn World Net Daily Alaskan cruise, I learn for the first time the difference between embryonic stem cell therapy and adult stem cell therapy. The media did not explain that Rick Perry's stem cell therapy was "adult" not "embryonic." The media never explains the fact that embryonic stem cell therapy is not working, it's a disaster, and adult stem cell therapy is working.
See the rest here:
" Embryonic" and "Adult" Stem Cell Research explained by David Kupelian
Benefits of STEM CELL THERAPY – Adipose Tissue
October 4th, 2011 10:47 pmFollow this link:
Benefits of STEM CELL THERAPY - Adipose Tissue
Adickes: Stem cell therapy
October 4th, 2011 10:47 pmDr. Mark Adickes discusses the use of stem cells in treating injured athletes.
Continue reading here:
Adickes: Stem cell therapy
Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami)
October 4th, 2011 10:47 pmCurrent treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells.
Read the original post:
Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami)